Posted by Michael Wonder on 23 Oct 2024
US FDA approves Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease
22 October 2024 - Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower respiratory tract disease caused by the respiratory syncytial virus.
Pfizer announced today that the US FDA has approved Abrysvo (respiratory syncytial virus vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by the respiratory syncytial virus in individuals 18 through 59 years of age who are at increased risk for lower respiratory tract disease caused by the respiratory syncytial virus.
